BioServe acquired Genomics Collaborative from SeraCare Life Sciences for $2 million cash and 7.5% royalty on net sales for five years.
“When the opportunity to acquire Genomics Collaborative presented itself, we jumped on it,” remarks Rama Modali, president, BioServe. “Genomics Collaborative had been a long time customer of BioServe, outsourcing much of their sample preparation and analysis work to BioServe. Through this relationship we became very familiar with the extraordinary quality and breadth of the sample collection and understood early on that a combination of BioServe’s genomic analysis capabilities with Genomics Collaborative’s samples bank would result in a highly unique and valuable solution for preclinical research programs in pharma and biotech.”
Genomics Collaborative will operate as a fully integrated division of BioServe. The company adds to its offering Genomics Collaborative’s Global Repository®, a library of 600,000 human DNA, tissue, and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients collected on four continents.
“Now, with the acquisition of one of the world’s largest commercial biobanks of human samples and data,” Modali continues, “Bioserve becomes the only global company having a massive repository of samples and proven infrastructure to fully extract the valuable information they contain—a true provider of a “biomaterials to validated data” genomics services platform. Bioserve can process, extract, genotype, and perform large-scale, case-control studies on DNA as well as serum and tissues.
“We also added a skilled biostatistician and experienced professionals in the areas of clinical affairs, business development, and sales,” Modali adds. “Therefore, Bioserve can now offer researchers in pharma/biotech access to samples and data, but also provide research services such as biomarker discovery or validation programs on over 25 critical human disease states.”